Bavarian Nordic Announces Grant of PRIME Eligibility from the European Medicines Agency for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

COPENHAGEN, Denmark, June 28, 2022 – Bavarian Nordic A/S (OMX:BAVA) announced today that the European Medicines Agency (EMA) has granted access to its priority medicines (PRIME) scheme for MVA-BN^® RSV in active immunization for the prevention of lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults ≥60 years of age. There are no approved vaccines for RSV, and access to PRIME has been granted upon an assessment that the available clinical data overall show the potential of MVA-BN-RSV to address the unmet medical need in the proposed target population.